Abstract Details

Title Development and Validation of the Nottingham Oncologic Vertebral Algorithm (NOVA Score) for Surgical Triage in Metastatic Spinal Cord Compression

Topic Neuro-oncology

Presentation(s) S13 - Neuro-oncology: Advances in Diagnosis and Treatments (1:48 PM-2:00 PM)

Poster/Presentation
Number 005

Objective

To develop and validate the Nottingham Oncologic Vertebral Algorithm (NOVA) Score, a pragmatic, surgeon-oriented tool for predicting 12-month survival in patients with metastatic spinal cord compression (MSCC), and to compare its performance to established prognostic scores and oncologist estimates.

Background

Surgical decompression in MSCC improves outcomes in certain patients but not in every patient. Existing prognostic models were proving to be complex and inconsistently validated whereas reliance on subjective clinical decision was leading to variability in patient selection. There was a need for a simple, reproducible and highly sensitive scoring system for surgical triage which promted this study in developing the NOVA score.

Design/Methods Two independent cohorts of patients with MSCC referred for surgical consideration were included from a tertiary spine center: a derivation cohort (n = 184) and a validation cohort (n = 100). Feature selection was performed using random forest analysis, multivariable logistic regression, and permutation-based variable importance. The final NOVA Score incorporated three clinical parameters: Karnofsky Performance Status (KPS), primary tumor category, and presence of extraspinal metastases. The score ranges from 0–10, with a threshold of ≥7 used to predict >12-month survival. Predictive performance was assessed using accuracy, F1-score, area under the receiver operating characteristic curve (AUC), Cohen’s kappa, and calibration plots.

Results In the validation cohort, the NOVA Score achieved an accuracy of 71.0%, AUC of 0.693, F1-score of 47.3% for >12-month survival, and Cohen’s kappa of 0.28. Calibration plots showed good agreement in the mid-to-high probability range. Compared to the Revised Tokuhashi Score, OSRI, Modified Bauer Score, and oncologist estimates, NOVA demonstrated superior sensitivity for identifying long-term survivors using only three readily available variables.

Conclusions

The NOVA Score is a simple, reproducible tool for early prognostication in MSCC. Its minimal input requirements and balanced performance support its utility for surgical triage in multidisciplinary settings. Further external validation is warranted.

Authors/Disclosures
Vaishnavi Sharma, MBBS PRESENTER	Dr. Sharma has nothing to disclose.
Rodrigo Muscogliati, MBBS	Dr. Muscogliati has nothing to disclose.
Elie Najjar, MD	Mr. Najjar has nothing to disclose.
Shahbaz KHAN, MD	Dr. KHAN has nothing to disclose.
Khalid M. Salem, MD, PhD	Mr. Salem has nothing to disclose.

��ɫ��

��ɫ��